A 68-year-old woman was admitted because of severe abdominal distention with tenderness. Two months ago, a diffuse enlarged pancreas with rim-like enhancement [ Figure 1a , white arrows] and irregular narrowing of the main pancreatic duct [ Figure 1b , white arrows] were detected by computed tomography (CT) and magnetic resonance cholangiopancreatography, respectively. EUS-FNA of the pancreatic tail was performed with a transgastric approach using a 19-gauge needle [ Figure 1c , white arrowheads]. She was diagnosed as having autoimmune pancreatitis (AIP). Oral prednisolone therapy (30 mg daily) was started followed by tapering every 2 or 4 weeks. Two months after EUS-FNA, she was admitted again with the aforementioned symptoms. EUS-FNA is generally considered a safe procedure. [1, 2] We experienced delayed pancreatic ductal leakage after EUS-FNA for AIP. Some patients with pseudocysts associated with AIP who respond to steroids have been reported. [3] Heo et al. reported a case of pancreatic ascites, pancreatic ductal leakage, and multiple pseudocysts with AIP; the ascites with pseudocyst improved with corticosteroid therapy and endoscopic transpapillary stenting of the main pancreatic duct. [4] Although our patient was taking adequate prednisolone orally, fluid collection gradually increased within 2 months after EUS-FNA. Delayed pancreatic ductal leakage may be affected by delayed wound healing with steroid therapy, resolution of swelling, and weakness
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of the pancreatic duct with active inflammation due to AIP. Physicians should consider delayed pancreatic ductal leakage after EUS-FNA in patients with AIP receiving steroid therapy.
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